Publikasi Scopus 2024 per tanggal 31 Maret 2024 (233 artikel)

Publikasi Scopus 2024 per tanggal 31 Maret 2024 (233 artikel)

Jasim S.A.; Aziz D.Z.; Mustafa Y.F.; Margiana R.; Al-Alwany A.A.; Hjazi A.; Alawadi A.; Yumashev A.; Alsalamy A.; Fenjan M.N.
Jasim, Saade Abdalkareem (58881570900); Aziz, Dhifaf Zeki (57191330289); Mustafa, Yasser Fakri (57203725947); Margiana, Ria (56685900600); Al-Alwany, Ameen Abdulhasan (57221750032); Hjazi, Ahmed (57226852880); Alawadi, Ahmed (58139297400); Yumashev, Alexey (57189510951); Alsalamy, Ali (58539263200); Fenjan, Mohammed N. (57219128237)
58881570900; 57191330289; 57203725947; 56685900600; 57221750032; 57226852880; 58139297400; 57189510951; 58539263200; 57219128237
Role of genetically engineered mesenchymal stem cell exosomes and LncRNAs in respiratory diseases treatment
2024
Pathology Research and Practice
254
155135
0
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85184061941&doi=10.1016%2fj.prp.2024.155135&partnerID=40&md5=8e24b66ef6c8f10b47868238f1ee15b1
Medical Laboratory Techniques Department, Al-maarif University College, Anbar, Iraq; College of Science, Department of pathological Analyses, University of Kufa, Al-Najaf, Iraq; Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, Iraq; Department of Anatomy, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Master's Programme Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; University of Baghdad, college of medicine, Baghdad, Iraq; Department of Medical Laboratory, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Saudi Arabia; College of technical engineering, the Islamic University, Najaf, Iraq; College of technical engineering, the Islamic University of Al Diwaniyah, Al Diwaniyah, Iraq; College of technical engineering, the Islamic University of Babylon, Babylon, Iraq; Department of Prosthetic Dentistry, Sechenov First Moscow State Medical University, Russian Federation; College of technical engineering, Imam Ja'afar Al-Sadiq University, Al-Muthanna, 66002, Iraq; College of Health and Medical Technology, Al-Ayen University, Thi-Qar, Iraq
Jasim S.A., Medical Laboratory Techniques Department, Al-maarif University College, Anbar, Iraq; Aziz D.Z., College of Science, Department of pathological Analyses, University of Kufa, Al-Najaf, Iraq; Mustafa Y.F., Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, Iraq; Margiana R., Department of Anatomy, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Master's Programme Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Al-Alwany A.A., University of Baghdad, college of medicine, Baghdad, Iraq; Hjazi A., Department of Medical Laboratory, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Saudi Arabia; Alawadi A., College of technical engineering, the Islamic University, Najaf, Iraq, College of technical engineering, the Islamic University of Al Diwaniyah, Al Diwaniyah, Iraq, College of technical engineering, the Islamic University of Babylon, Babylon, Iraq; Yumashev A., Department of Prosthetic Dentistry, Sechenov First Moscow State Medical University, Russian Federation; Alsalamy A., College of technical engineering, Imam Ja'afar Al-Sadiq University, Al-Muthanna, 66002, Iraq; Fenjan M.N., College of Health and Medical Technology, Al-Ayen University, Thi-Qar, Iraq
The term acute respiratory disease encompasses a wide range of acute lung diseases, which in recent years have been ranked among the top three deadly diseases in the world. Since conventional treatment methods, including the use of anti-inflammatory drugs, have had no significant effect on the treatment process of these diseases, the attention of the medical community has been drawn to alternative methods. Mesenchymal stem cells (MSC) are multipotential stem/progenitor cells that have extensive immunomodulatory and anti-inflammatory properties and also play a critical role in the microenvironment of injured tissue. MSC secretomes (containing large extracellular vesicles, microvesicles, and exosomes) are a newly introduced option for cell-free therapies that can circumvent the hurdles of cell-based therapies while maintaining the therapeutic role of MSC themselves. The therapeutic capabilities of MSCs have been showed in many acute respiratory diseases, including chronic respiratory disease (CRD), novel coronavirus 2019 (COVID −19), and pneumonia. MSCs offer novel therapeutic approaches for chronic and acute lung diseases due to their anti-inflammatory and immunomodulatory properties. In this review, we summarize the current evidence on the efficacy and safety of MSC-derived products in preclinical models of lung diseases and highlight the biologically active compounds present in the MSC secretome and their mechanisms involved in anti-inflammatory activity and tissue regeneration. © 2024 Elsevier GmbH
Cell-free therapies; Immunomodulation; Inflammation; Mesenchymal stem cell; Respiratory disease; Tissue regeneration
long noncoding RNA cancer susceptibility candidate 2; long noncoding RNA cancer susceptibility candidate 9; long noncoding RNA growth arrest special 5; long noncoding RNA metastasis associated lung adenocarcinoma transcript 1; long noncoding RNA NRAV; long noncoding RNA nuclear paraspeckle assembly transcript 1; long untranslated RNA; unclassified drug; long untranslated RNA; alpha 1 antitrypsin deficiency; antiinflammatory activity; asthma; cell proliferation; chronic obstructive lung disease; coronavirus disease 2019; exosome; fibroblast; fibrosing alveolitis; genetic engineering; human; macrophage; mesenchymal stem cell transplantation; nonhuman; pathogenesis; phenotype; pneumonia; protein expression; pyroptosis; respiratory tract disease; Review; tissue regeneration; upregulation; acut
Elsevier GmbH
03440338
38295461
Review
Q2
652
7794

Unit Riset FKUI/Medical Research Unit
Gedung IMERI Tower Riset lt. 9, Jl. Salemba Raya No. 6, Jakarta Pusat, 10430
Telp. : +62 21 29189160 (ext. 201912)
E-mail : manajer.riset.fkui1@gmail.com